Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

Arabul M., GÜLLÜLÜ M., YILMAZ Y., Akdag I., Kahvecioglu S., Eren M. A., ...Daha Fazla

CLINICAL BIOCHEMISTRY, cilt.41, sa.13, ss.1055-1058, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 13
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1016/j.clinbiochem.2008.05.010
  • Dergi Adı: CLINICAL BIOCHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1055-1058
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Objectives: Anemia, low-grade inflammation and/or alterations in lipid metabolism are common findings in individuals with end-stage renal disease (ESRD) despite advances in dialysis treatment. Hepcidin, a key regulator of iron metabolism, may play an important role in the interdependence of inflammation and anemia in ESRD patients. Statins may reduce cardiovascular events in dialysis patients and have pleiotropic effects in addition to lowering total and low-density lipoprotein (LDL)-cholesterol.